New York, NY -- (SBWIRE) -- 03/07/2018 -- Description:

This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy for ovarian cancer including molecules at various development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as route of administration and target.

Ovarian cancer has the lowest survival rate among all gynecological cancers. Epithelial ovarian cancer (EOC) is identified as the most common ovarian cancer. The administration of chemotherapy products has shown long-lasting side effects in various cancer patients. This is inducing an increase in the number of research studies focusing on overcoming such challenges, which in turn, is indicating gene therapy to be the next big paradigm shift in pharmacology. The market research analysts have predicted that with the emergence of gene therapy as an approach for the treatment of ovarian cancer, the global ovarian cancer market will witness considerable growth in the coming years. With the potential to cure ovarian cancer by replacing faulty genes with normal ones, replacement gene therapy will gain prominence during the next few years.

The pipeline analysis report, companies are focusing on evaluating pipeline molecules for recurrent ovarian epithelial cancer and platinum-resistant ovarian cancer. Our market research analysts have also identified that most of the gene therapy candidates in the pipeline are being development for platinum-resistant ovarian cancer.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/2771231-gene-therapy-for-ovarian-cancer-a-pipeline-analysis-report

For more information or any query mail at sales@wiseguyreports.com

Companies covered
This pipeline analysis report provides a comprehensive analysis of the companies that are involved in the development of gene therapy molecules for the treatment of ovarian cancer. The report provides detailed information on the various stages of molecules developed by companies for different indications. Furthermore, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –
- Takara Bio
- VBL Therapeutics
- CELSION
- Targovax

Therapeutic assessment of the gene therapy for ovarian cancer by route of administration
- Intravenous
- Intratumoral
- Intraperitoneal

The walls of abdominal organs such as the stomach and intestines and the abdominal (peritoneal) cavity are lined with a thin and transparent membrane called peritoneum. According to our research experts, majority of gene therapy molecules currently in the pipeline for ovarian cancer are developed for intraperitoneal route of administration, in which, the drug is administered directly into the peritoneum.

Therapeutic assessment of the gene therapy for ovarian cancer by target
- NY-ESO-1
- p53 gene
- IL – 12
- Thymidine Kinase

According to this pipeline analysis report, the current pipeline molecules for ovarian cancer gene therapy are mainly evaluated by NY-ESO-1 target therapeutic assessment. However, several companies have not disclosed the target for most of the molecules in the early development stages.

Key questions answered in the report include
- What are the gene therapy molecules in the various development stages for ovarian cancer?
- What are the companies that are currently involved in the development of gene therapy molecules for ovarian cancer?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule.

Report Details @ https://www.wiseguyreports.com/reports/2771231-gene-therapy-for-ovarian-cancer-a-pipeline-analysis-report

Table Of Contents – Major Key Points

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: GENE THERAPY FOR OVARIAN CANCER: AN INSIGHT
- Introduction

PART 05: MAJOR REGULATORY AUTHORITIES
- US
- Europe
- Japan
- Australia
- China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS
- Mid-stage molecules (Phase II and I/II), 2017
- Early-stage molecules (Phase I), 2017
- Inactive molecules, 2017

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 10: THERAPEUTIC ASSESSMENT (BY TARGET)

PART 11: KEY COMPANIES
- Active companies: Category and parameters
- APPENDIX
- List of abbreviations

Continue……

For more information or any query mail at sales@wiseguyreports.com

About Wise Guy Reports
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.